HOPA 2018 Highlights

Chicago, IL—People often use the terms “value” and “quality” interchangeably, but they are not the same. In the healthcare landscape, value pertains to health outcomes that matter to patients, taking into account the cost of delivering those outcomes, whereas the Institute of Medicine defines quality as “the degree to which health services for individuals and populations increase the likelihood of desired health outcomes and are consistent with current professional knowledge.”
A claims analysis of elderly patients with pancreatic cancer has shown that those receiving early palliative care consultations had lower healthcare utilization than patients who received late palliative care. Data presented at ASCO 2018 showed that patients who received palliative care within 4 weeks of diagnosis had fewer visits to the emergency department (2.4 vs 3.0, respectively; P <.001) and lower emergency department–related costs ($3043 vs $4117, respectively; P <.001). According to the study investigators, these findings provide real-world evidence to support oncology societies’ recommendations for the early integration of palliative care.
According to Julie Kinnerly-Shah, PharmD, MS, MHA, BCPS, one of the most important things to consider when implementing CAR T-cell therapy is the various roles and responsibilities that are required.
Chicago, IL—Business intelligence is the process of collecting data from disparate systems internally and externally, and turning it into information that is meaningful and actionable toward achieving strategic goals.
In response to these gaps in the literature, Dr Palumbo and her colleagues sought to evaluate whether patient-centered therapy management software, in conjunction with use of electronic medical records (EMRs), would be valuable in completing pharmacist activities and capturing patient outcomes.

At the 2018 Hematology/Oncology Pharmacy Association Annual Conference, Jaime Anderson, PharmD, BCOP, reviewed recent efficacy and safety data on immune checkpoint inhibitor regimens in melanoma, and discussed disease-specific characteristics that may guide treatment-planning decisions.

At the 2018 Hematology/Oncology Pharmacy Association Annual Conference, Dr Seddon provided attendees with an overview of FLT3-mutated AML, including currently available treatments, mechanisms of resistance, and future directions.

At the 2018 Hematology/Oncology Pharmacy Association Annual Conference, Josiah Land, PharmD, BCOP, and Jacob Kettle, PharmD, BCOP, discussed the realities of using PD-L1 as a biomarker in oncology in the front- and second-line settings.


Results 1 - 8 of 8